Seraxis

Cell Therapy / Regenerative Medicineseraxis.com

Seraxis is a privately owned biotechnology company.

Company typePrivate
Founded2013
HeadquartersGermantown, United States
Headcount11–50
GTM typeB2C
OfferingHardware or Manufacturing

What Seraxis does

Seraxis is a private biotechnology company launched in March 2013. Incorporated in Singapore and the United States, their GMP lab is located in Germantown, Maryland. Seraxis team of scientists developed novel cell and encapsulation technologies. Their main goal is to bring a practical cell therapy for insulin-dependent diabetes to the clinic and provide a long term cure to patients that does not require the use of immuno-suppression. Their corporate structure and strategy is designed to achieve that goal as quickly as possible, while bringing maximum value to their shareholders.

Seraxis firmographics

Firmographics

Name: Seraxis
Legal name: Seraxis, Inc.
Website: https://seraxis.com
Company type: Private
Founded year: 2013
Operating status: Operating
Headcount range: 11–50 employees
Short description: Seraxis is a privately owned biotechnology company.
Ownership category
akta.pro rank

Seraxis industry classification

Industry

Product category: Cell Therapy / Regenerative Medicine
NAICS: Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC: Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry: Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)

Keywords

Cell replacement therapy
Regenerative medicine
Islet replacement therapy
Diabetes treatment
Stem cell therapy

Where Seraxis is headquartered

Location

Headquarters

HQ city: Germantown
HQ country: United States
HQ region: North America

Offices1 record

Markets served

Seraxis business model

Business model

GTM type: B2C
Offering type: Hardware or Manufacturing
Cost components: Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

Cell Replacement Therapy Commercialization: Pre-commercial biotech company developing a cell replacement therapy for insulin-dependent diabetes. No current revenue; development stage with SR-02 in clinical trials following FDA IND allowance in October 2024.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Seraxis product offering

Product offering

Core offering

Seraxis is a regenerative medicine company developing stem cell-derived pancreatic islet replacement therapies for insulin-dependent diabetes. Its lead product SR-02 is a cell replacement therapy using pancreatic endocrine cell clusters derived from a proprietary stem cell line, designed to restore physiological glucose regulation in Type 1 diabetes patients without requiring lifelong immunosuppression. The company received FDA IND allowance for SR-02 in October 2024 and is advancing toward clinical trials.

Product overview

Seraxis is a regenerative medicine company developing cell replacement therapies for insulin-dependent diabetes. The company offers a portfolio of pancreatic cell products: SR-02 (islet replacement therapy, FDA IND-cleared for clinical study), SR-03 (genetically modified universal allogenic cell line), Synthetic Replacement Endocrine Clusters (SRE), and pancreatic organoids. All products are manufactured from proprietary stem cell lines engineered from donor pancreatic islets, designed to restore normal glucose control without requiring lifelong immune suppression.

Differentiator

Problem solved

Functional benefit

Products and services

SR-02 Islet Replacement Therapy Clinical-stage cell replacement therapy for Type 1 Diabetes that uses engineered pancreatic endocrine cell clusters derived from Seraxis's proprietary stem cell line to restore normal glucose control. FDA IND allowance received October 2024; intended to be delivered as a one-time outpatient implantation without lifelong immunosuppression.
SR-03 Genetically Modified Pancreatic Cell Line Preclinical genetically modified pancreatic cell line engineered as a universal allogeneic transplant therapy targeting both Type 1 and insulin-requiring Type 2 diabetes without requiring lifelong immune suppression.
Pancreatic Endocrine Cell Clusters Manufactured pancreatic endocrine cell clusters that replace native pancreatic cells to regulate blood glucose, secreting precise amounts of insulin, glucagon, and other hormones. Produced under a 21 CFR Part 210 and 211 compliant manufacturing process.
Pancreatic Organoids Pancreatic organoids derived from Seraxis's novel pancreas-derived stem cells, used as a research and preclinical platform for diabetes therapy development.

Quantifiable outcome

Reversed diabetes in animal models
+1 more outcomes

Companies that use Seraxis

Customer profile

Segments1 record

Seraxis technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Seraxis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

Medytox Inc.coreStrategic or Co-development Partner · 10 August 2016Seraxis closed a Series B financing round and entered into a collaboration with Medytox Inc. This represents a strategic partnership combining Seraxis' cell therapy technology with Medytox's capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Seraxis competitors and assessment

Company assessment

Direct peers

Vertex Pharmaceuticals: Vertex is developing VX-880 and VX-264, stem cell-derived islet cell therapies for Type 1 diabetes (acquired Semma Therapeutics). It is the most directly comparable competitor targeting the same patient population with a similar mechanistic approach, but with substantially greater clinical and financial resources.
ViaCyte: Pioneer in stem cell-derived pancreatic progenitor cell therapies for T1D; was acquired by Vertex in 2022 to form the basis of VX-264. Directly comparable as a peer in encapsulated stem cell-derived islet replacement therapy.
Semma Therapeutics: Founded to commercialize Doug Melton's stem cell-derived islet cell work for T1D; acquired by Vertex Pharmaceuticals in 2019 for $950M. Closest mechanistic peer to Seraxis in producing functional beta cells from stem cells for diabetes treatment.
Sigilon Therapeutics: Developed encapsulated cell therapies (including for Type 1 diabetes) using its Afibromer biomaterial platform to enable implant function without immunosuppression. Comparable approach of combining cell therapy with immune-evasion/encapsulation to treat T1D.

Broad incumbents

CRISPR Therapeutics: Gene-editing biotechnology company developing CTX211 (allogeneic, gene-edited, stem cell-derived beta cell precursor therapy for T1D) with ViaCyte/Vertex. Comparable as a cell therapy platform with immune-evasion engineering, though broader in indication scope.
Novo Nordisk: Global leader in diabetes care with established insulin and emerging cell therapy efforts (e.g., stem cell-derived islet research collaborations). Highly relevant as a strategic potential partner/acquirer and as the incumbent player Seraxis aims to disrupt in T1D treatment.
Eli Lilly: Lead investor in Seraxis's Series C and a major incumbent in diabetes therapeutics with growing cell therapy ambitions. Both a strategic investor/partner candidate and a broad incumbent whose own pipeline decisions directly affect Seraxis's strategic options.
AT132 (Astellas): Astellas (via Universal Cells and acquisition of Quethera) is developing regenerative medicine and cell/gene therapies. Comparable as a large pharma developing cell-based regenerative approaches with potential interest in islet cell replacement programs.

Emerging players

Provention Bio: Focused on immune-mediated diseases including Type 1 Diabetes (teplizumab for delay of T1D onset). Comparable as a T1D-focused biotech pursuing disease-modifying approaches, though focused on immunomodulation rather than cell replacement.
TolerogenixX: Clinical-stage biotech developing cellular immunotherapy approaches to induce immune tolerance in transplantation, including islet cell transplantation. Comparable for its overlap in transplantation immunology and immune tolerance - a key enabling area for Seraxis's therapy.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Seraxis compliance and trust

Trust signal

Compliance3 records

Seraxis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seraxis leadership team

Management profile

Number of profiles

Profiles9 records

Seraxis funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seraxis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seraxis

What does Seraxis do?

Is Seraxis a public or private company?

Seraxis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Seraxis founded?

Seraxis was founded in 2013. It employs 11 to 50 people.

Where is Seraxis based?

Seraxis is headquartered in Germantown, United States, in the North America region.

How does Seraxis make money?

One revenue line is on record: cell Replacement Therapy Commercialization.

Who are Seraxis's main competitors?

Direct peers on record are Vertex Pharmaceuticals, ViaCyte, Semma Therapeutics and Sigilon Therapeutics. Broad incumbents are CRISPR Therapeutics, Novo Nordisk, Eli Lilly and AT132 (Astellas). Emerging players are Provention Bio and TolerogenixX.

Does Seraxis have an API?

No public API is recorded for Seraxis.

What industry is Seraxis in?

Seraxis's product category is Cell Therapy / Regenerative Medicine. Its primary akta.pro industry code is HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.